stockrowSpero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024.
- Revenue
- −95.6%
- EPS
- −433.3%
- Free cash flow
- +69.7%
Quarter to June 2026, against a year earlier
Follow SPRO
Alert me
Spero Therapeutics, Inc. (SPRO) EV/Sales
As of 6 November 2026, Spero Therapeutics, Inc. (SPRO) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −31.1× (February 2018) to 60.5× (April 2018); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 2,241.77% |
| FY2024 | 0.1× | 58.52% |
| FY2023 | 0.0× | — |
| FY2022 | −0.8× | — |
| FY2021 | 19.1× | (42.06%) |
| FY2020 | 32.9× | 544.73% |
| FY2019 | 5.1× | — |
| FY2018 | −4.3× | — |
| FY2017 | −28.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.3× | (5.77%) |
| Dec 2025 | 1.4× | (4.20%) |
| Sep 2025 | 1.4× | (47.81%) |
| Jun 2025 | 2.7× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | −93.0× |
| XBIT XBiotech Inc. compare | −10.5× |
| FBIO Fortress Biotech, Inc. compare | −1.5× |
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| SPRO Spero Therapeutics, Inc. | 0.2× |
| GOSS Gossamer Bio, Inc. compare | 4.1× |
| CRDF Cardiff Oncology, Inc. compare | 39.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)